Clinical Trials
4 trialsNCT02834013 2026-06-03
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07576725 2026-05-08
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
Phase 2 Not yet recruiting
NCT06683846 2025-08-24
Ivonescimab in the Treatment of Multiple Advanced Tumors
Fudan University
Phase 2 Recruiting
NCT05329792 2023-10-06
IntriNSiC
Philogen S.p.A.
Phase 2 Unknown